Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2017
At a glance
- Drugs Dalotuzumab (Primary) ; MK 0752 (Primary) ; MK 2206 (Primary) ; Ridaforolimus (Primary)
- Indications Colon cancer; Colorectal cancer; Non-small cell lung cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 01 Mar 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 30 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Nov 2012 Planned end date changed from 1 Apr 2014 to 1 May 2013 as reported by ClinicalTrials.gov.